ISCO is dedicated to ensuring you stay informed during the COVID-19 crisis. Click above to find all of the latest resources from ASCO, ASH, COA, HOSS, and important Industry News related to the crisis.
BREAKING NEWS: National healthcare organizations urge Governors and Insurance Commissioners throughout the country to support broad coverage and payment of telemedicine services even after the COVID-19 pandemic ends. Read the letters to the Governors and the Insurance Commissioners here.
The Idaho Society of Clinical Oncology (ISCO) represents Idaho physicians and related health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.
The Benefits of Membership
Membership in the Society is open to all professionals whose primary endeavor is the delivery of oncology care, including physicians, nurse practitioners, physician assistants and pharmacists. Membership is restricted to those individuals primarily delivering care in the State of Idaho and is FREE to qualified professionals
CORONAVIRUS INFORMATION FROM THE CDC
CDC is working across the Department of Health and Human Services and across the U.S. government in the public health response to COVID-19.
Please see links below for additional information:
ONLINE RESOURCES
RxVantage recently shared a panel discussion of oncology experts from around the country who have exhibited impressive leadership amid COVID-19. These executives met via video conference to share experiences, discuss strategies that have worked (as well as those that have not), and their plans for moving forward. Click below to view each presentation:
Most Favored Nation Interim Final Rule Will Devastate Cancer Care
The American Society of Clinical Oncology (ASCO) filed an amicus curiae brief in support of motions in three cases to stop the Most Favored Nation (MFN) model from taking effect on January 1, 2021. ASCO’s brief urges the court to stop implementation of the model, citing its devastating impact on patients. CMS projects that the model will cause 19% of beneficiaries to lose access to its 50 targeted drugs, 38 of which are used in cancer treatment. In addition, ASCO estimates that independent community oncology practices will see a 52% average loss of Medicare drug revenue once the model is fully phased in and that hospital outpatient oncology departments will see an average loss of 50% by year four of the model. Read the Society’s full amicus curiae brief and comments submitted to CMS about the MFN Model.
Current news
- January 7, 2011 - Congress recently passed an end-of-year legislative package that provides federal funding for Fiscal Year (FY) 2021 and includes numerous provisions that will directly impact patients with cancer and their entire cancer care team. Find out more
- December 10, 2020 - Community Oncology Alliance Applauds Supreme Court Ruling Supporting State Regulations of PBMs, Find out more
- October 13, 2020 - The Latest Circuit Court Ruling on 340B Program Effect on Practices, Find out more
- October 8, 2020 - On October 2, after consultation with public health officials, Department of Health and Human Services (HHS) Secretary Alex Azar, pursuant to the authority vested in him under section 319 of the Public Health Service Act, renewed the public health emergency effective October 23, 2020.
- October 6, 2020 - Supreme Court scrutinizes Arkansas law that regulates PBM payments to pharmacies, Find out more
ISCO is happy to have partnered with NCODA to present their most recent webinars. You can watch all five parts of the COVID-19 series and a special ASCO/NCODA webinar on Patient-Centered Standards for Medically Integrated Dispensing by clicking HERE.
IMPORTANT INFORMATION FOR ALL PROVIDERS
FROM THE AMERICAN MEDICAL ASSOCIATION
As of January 1, 2021, there will be significant changes to the office and outpatient Evaluation and Management (E&M) services (CPT ® codes 99202-99215) for both new and established patients.
|
